EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ESR1 methylation and ESR1 mutations in circulating tumor cells ( CTCs ) and paired plasma‐ cfDNA of advanced breast cancer patients: A feasibility proof‐of‐concept study

Dimitra Stergiopoulou iD, Athina Markou iD, Eleonora Nicolo, Mara S Serafini, Qiang Zhang, Youbin Zhang, Lorenzo Gerratana, Andrew A Davis, Huiping Liu, William J Gradishar, Carolina Reduzzi, Massimo Cristofanilli und 1 weitere

Molecular Oncology · 2026-08 · 20 (8) · 2102-2113

DOI: 10.1002/1878-0261.70254 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 27.05.2026. Verfasst von Dimitra Stergiopoulou und 12 weiteren Autor:innen. Beteiligte Einrichtung: Analysis of Circulating Tumor Cells, Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, Athens, Greece. Hauptthemen laut MEDLINE: Estrogen Receptor alpha, Neoplastic Cells, Circulating, Breast Neoplasms, DNA Methylation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, Lynn Sage Cancer Research Foundation, Stavros Niarchos Foundation / grant number 16785.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endocrine resistance is a complex phenomenon, including alterations of the ESR1 gene. The aim of this study was to simultaneously analyze ESR1 promoter methylation and ESR1 hotspot mutations in circulating tumor cells (CTCs) and paired plasma‐circulating tumor DNA (ctDNA) from patients with estrogen receptor‐positive (ER+) advanced breast cancer (BC). We retrospectively analyzed samples from 42 ER+ advanced BC patients characterized for CTCs and ctDNA at Northwestern University. CTCs were enumerated using the CellSearch® system, while ctDNA was analyzed with the Guardant360 NGS platform. Genomic DNA from CellSearch‐enriched CTC fractions was amplified and analyzed using the ESR1‐NAPA assay. ESR1 methylation analysis was performed in 34 samples. ESR1 mutations were detected in 59.5% CTC‐derived samples, a significantly higher proportion than in paired plasma ctDNA (29.6%). ESR1 methylation was observed in 26.5% patients. Concurrent ESR1 mutations and methylation were identified in six cases, suggesting combined genetic and epigenetic mechanisms of endocrine resistance. Overall, CTC‐derived genomic DNA showed higher sensitivity for detecting ESR1 mutations than plasma ctDNA, supporting the potential value of CTC analysis for characterizing endocrine resistance in advanced BC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Estrogen Receptor alphaNeoplastic Cells, CirculatingBreast NeoplasmsDNA MethylationMutationCirculating Tumor DNAHumansFemaleMiddle AgedAgedFeasibility StudiesAdultProof of Concept StudyPromoter Regions, Genetic

Stichwörter der Autor:innen

CTCsESR1 methylationESR1 mutationsbreast cancerctDNAliquid biopsy

Substanzen

Estrogen Receptor alphaESR1 protein, humanCirculating Tumor DNA

Autor:innen und Institutionen

  • Analysis of Circulating Tumor Cells, Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, Athens, Greece.
  • Division of Hematology and Medical Oncology, Weill Cornell Medicine/New York-Presbyterian Hospital, New York, NY, USA.
  • Robert H. Lurie Cancer Center of Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.
  • Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.
  • Division of Oncology, Washington University, St. Louis, MO, USA.

ORCID-Profile: Dimitra Stergiopoulou, Athina Markou, Evi Lianidou

Förderung

  • NCATS NIH HHS
  • Lynn Sage Cancer Research Foundation
  • Stavros Niarchos Foundation / grant number 16785
  • Lynn Sage Breast Cancer Foundation

Zitieren

APA

Stergiopoulou, D., Markou, A., Nicolo, E., Serafini, M. S., Zhang, Q., Zhang, Y., Gerratana, L., Davis, A. A., Liu, H., Gradishar, W. J., Reduzzi, C., Cristofanilli, M., & Lianidou, E. (2026). ESR1 methylation and ESR1 mutations in circulating tumor cells ( CTCs ) and paired plasma‐ cfDNA of advanced breast cancer patients: A feasibility proof‐of‐concept study. Molecular Oncology, 20(8), 2102-2113. https://doi.org/10.1002/1878-0261.70254

Vancouver

Stergiopoulou D, Markou A, Nicolo E, Serafini MS, Zhang Q, Zhang Y, et al. ESR1 methylation and ESR1 mutations in circulating tumor cells ( CTCs ) and paired plasma‐ cfDNA of advanced breast cancer patients: A feasibility proof‐of‐concept study. Molecular Oncology. 2026;20(8):2102-2113. doi:10.1002/1878-0261.70254

BibTeX
@article{Stergiopoulou2026,
  author = {Stergiopoulou, Dimitra and Markou, Athina and Nicolo, Eleonora and Serafini, Mara S and Zhang, Qiang and Zhang, Youbin and Gerratana, Lorenzo and Davis, Andrew A and Liu, Huiping and Gradishar, William J and Reduzzi, Carolina and Cristofanilli, Massimo and Lianidou, Evi},
  title = {ESR1 methylation and ESR1 mutations in circulating tumor cells ( CTCs ) and paired plasma‐ cfDNA of advanced breast cancer patients: A feasibility proof‐of‐concept study},
  journal = {Molecular Oncology},
  year = {2026},
  volume = {20},
  number = {8},
  pages = {2102--2113},
  doi = {10.1002/1878-0261.70254}
}
Kostenlos starten →